Clinical trials: Liver Transplant Rejection
Complication of Transplanted Liver
Donor Specific HLA Alloantibodies in Liver Transplantation
The aim is to evaluate the impact of donor specific HLA alloantibodies (DSA) on all-cause mortality and re-transplantation, early allograft dysfunction, acute and chronic rejection, fibrosis, vascular, and biliary complications.
- Trial name
- NCT02784080
- Testing
- HLA-alloantibodies exposure
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 858 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Acute Liver Failure, Acute-On-Chronic Liver Failure
Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Efficient immunosuppressive therapy and improved surgical techniques have developed liver transplantation as a well-established and life-saving treatment. The 1-year survival rate of approximately 85-90%.
- Conditions
- Acute Liver Failure, Acute-On-Chronic Liver Failure, Liver Cirrhosis
- Trial name
- NCT04621812
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Transplantation, Auxiliary Liver Transplantation
Rejection After Auxiliary Partial Orthotopic Liver Transplantation: An Exploratory Comparison by Native-Liver Cirrhosis Status
This retrospective single-center cohort study aims to investigate the association between native-liver cirrhosis status and post-transplant outcomes in recipients undergoing auxiliary partial orthotopic liver transplantation…
- Trial name
- NCT07275008
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhi-Jun Zhu
Liver Diseases, Liver Dysfunction
Global Utilization And Registry Database for Improved preservAtion of doNor Livers
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor liver that were preserved and transported within the LIVERguard system, as well as…
- Conditions
- Liver Diseases, Liver Dysfunction, Liver Transplant Disorder, Liver Transplant Rejection
- Trial name
- NCT05082077
- Testing
- LIVERguard
- Where
- 15 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Paragonix Technologies
Autoimmune Diseases, Inflammation
Prospective Study of White Blood Cells
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
- Conditions
- Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver
- Trial name
- NCT04838171
- Testing
- White blood cell and blood collection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Quell Therapeutics Limited
Renal Function, Liver Transplant
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.
- Trial name
- NCT01598987
- Testing
- Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
- Where
- 32 sites in United States, Australia and 10 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Liver Diseases, Liver Cancer
CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection
This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation.
- Conditions
- Liver Diseases, Liver Cancer, Liver Cirrhosis, Liver Failure
- Trial name
- NCT07053488
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Liver Transplant Recipients, Liver Transplantation
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
The primary objective of this study is to assess the efficacy of immunosuppression withdrawal (ISW) in pediatric liver transplant (tx) recipients.
- Conditions
- Liver Transplant Recipients, Liver Transplantation, Immunosuppression
- Trial name
- iWITH (NCT01638559)
- Testing
- Immunosuppression withdrawal
- Where
- 12 sites in United States, Canada
- Volunteers
- 161 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplantation
Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C
Acute cellular rejection is relatively common after liver transplantation, typically does not affect graft survival, and is not associated with the development of chronic rejection.
- Trial name
- NCT01428700
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant, Liver Transplantation
Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients
Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ.
- Trial name
- WISP-R (NCT00320606)
- Testing
- Immunosuppression Withdrawal
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant Rejection, Liver Transplant Failure and Rejection
Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients
Liver transplantation is a lifesaving procedure; however, there are chances that the body may reject the organ following liver transplantation, and this remains a significant concern.
- Trial name
- NCT06153641
- Testing
- N/A-Observational Study
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Evidence of Liver Transplantation, Rejection
Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
This open-label clinical trial will evaluate the safety and efficacy of Alemtuzumab (Campath, Bayer Corp., Pittsburgh) in children (0-17) and adults (18-25) receiving intestinal transplant.
- Conditions
- Evidence of Liver Transplantation, Rejection, ALEMTUZUMAB
- Trial name
- NCT01208337
- Testing
- Alemtuzumab
- Volunteers
- 23 people
- Sponsor
- University of Pittsburgh
Heart Transplantation, Kidney Transplantation
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
Activity of genes in donor tissues that are involved in inflammation are thought to be involved with early organ dysfunction, increased immune responses in transplant recipients, and organ rejection.
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
- Trial name
- NCT00531921
- Where
- 5 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Transplant; Complications, Liver Transplant Rejection
Mortality, Morbidity and Risk Factors of Liver Retransplantation
This study aims to compare the short and long term outcomes of living donor and deceased donor liver retransplantation. Bearing that in mind, the investigators will retrospectively analyze the files of patients whom underwent a…
- Conditions
- Liver Transplant; Complications, Liver Transplant Rejection, Liver Transplant Failure, Liver Diseases
- Trial name
- NCT04789213
- Testing
- Liver Transplantation
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Memorial Bahçelievler Hospital
Liver Transplantation, Thymoglobulin
rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation
This open-label clinical trial will evaluate the pharmacodynamics, pharmacogenomics and early efficacy and safety of steroid-free Tacrolimus (TAC) monotherapy and its minimization after induction with rabbit, anti-human thymocyte…
- Conditions
- Liver Transplantation, Thymoglobulin, Rejection
- Trial name
- NCT01207141
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Pittsburgh
Heart Transplantation, Kidney Transplantation
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and…
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- NCT01614665
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 10 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Europe Ltd.
Chronic Rejection of Liver Transplant
Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance
The first trial will involve the generation of donor alloantigen-specific CD4+CD25+ Tregs from peripheral blood of pre-transplant patients, the administration of the CD4+CD25+ Tregs (1 x 106 cells/kg) at several intervals (for…
- Trial name
- Treg (NCT01624077)
- Testing
- Regulatory T cells
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Liver Transplant Failure, Antibody-mediated Rejection
Antibodies and Liver Retransplantation
Despite reports that associate donor specific antibody (DSA) with rejection after liver transplantation, grafts are still allocated according to blood group (ABO) but not human leukocyte antigen (HLA) compatibility, possibly due…
- Trial name
- NCT03815864
- Testing
- Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
- Volunteers
- 200 people
- Sponsor
- London Health Sciences Centre
Liver Transplant Failure and Rejection, Children, Only
Histologic Evolution of Patients With Liver Transplantation
Certain pediatric liver transplant patients with immunosuppression levels in the therapeutic range and normal liver function tests present histological alterations (inflammation or fibrosis) in protocol biopsies.
- Trial name
- NCT06103097
- Testing
- No interventions done (obervational)
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Vall d'Hebron